MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2024 International Congress

    Resting state EEG source analysis identifies distinct neural signature associated with impulse control disorders in PD

    E. Iglesias-Camacho, FJ. Gómez Campos, P. Franco Rosado, L. Garrote Espina, AM. Castellano-Gerrero, M. San Eufrasio, C. Perez-Calvo, L. Muñoz-Delgado, S. Jesús, D. Macías-García, E. Ojeda-Lepe, A. Adarmes-Gómez, F. Carrillo, JF. Martín-Rodriguez, P. Mir (Seville, Spain)

    Objective: To identify EEG source level differences between patients with Parkinson's disease (PD) and associated impulse control disorders (ICD) and patients without ICD. Background: Previous…
  • 2023 International Congress

    Impulse Control Disorder and medication management in Patients with Early-Onset Parkinson’s Disease

    J. Jacobson, K. Ghoniem, A. Mullan, P. Turcano, C. Stang, E. Camerucci, C. Piat, J. Bower, R. Savica (Rochester, USA)

    Objective: To assess the usage frequency of dopamine agonists (DA), the prevalence of impulse control disorder (ICD) in patients with Early-onset Parkinson’s Disease (EOPD), and…
  • 2023 International Congress

    The role of depression in the development of Impulse Control Disorders in Parkinson´s Disease.

    M. Vales Montero, F. Ferre Navarrete, J. Conejo Galindo, P. Melgarejo Otálora, P. Andrés Camarón, J. Suárez Campayo, R. Reyes Marrero, JR. López-Trabada Gómez, MB. Díaz Rodríguez, F. Grandas (Madrid, Spain)

    Objective: We aimed to investigate whether depression is associated with a higher risk of developing impulse control disorders (ICD) in Parkinson´s disease (PD) patients and…
  • 2023 International Congress

    Novelty Seeking: A Narrative Review

    K. Paulk, L. Neilson (Portland, USA)

    Objective: To explore novelty seeking (NS) as a construct, in both its adaptive and maladaptive roles, in order to provide insight into the cognitive and…
  • 2023 International Congress

    Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease

    V. Fung, J. Aldred, F. Bergquist, E. Danielsen, A. Jeong, J. Jia, A. Spiegel, S. Talapala, C. Carroll (Westmead, Australia)

    Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…
  • 2023 International Congress

    REM sleep behavior disorder in Parkinson´s Disease: a risk factor for Impulse Control Disorders.

    M. Vales Montero, A. Contreras Chicote, B. Delacasa Fages, J. Pérez Sánchez, E. Luque Buzo, M. González Sánchez, F. Grandas (Madrid, Spain)

    Objective: We aimed to analyze de association between REM sleep behavior disorder (RBD) and impulse control disorders (ICD) in Parkinson´s disease (PD) patients and in…
  • 2023 International Congress

    The efficacy of dopamine agonists or monoamine oxidase type B inhibitors as monotherapy in patients with early Parkinson disease: A network meta-analysis

    CSC. Chuang (Changhua, Taiwan)

    Objective: This study aimed to investigate the effectiveness of dopamine agonists or monoamine oxidase type B inhibitors (MAOB-I) as monotherapy in patients with early Parkinson's…
  • 2023 International Congress

    Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson’s disease uncontrolled by levodopa: final results of the PD MED LATER randomized clinical trial

    C. Clarke, C. Rick, S. Patel, R. Wooley, N. Rowland, J. Futterer, R. Ottridge, C. Jenkinson, R. Gray (Birmingham, United Kingdom)

    Objective: PD MED LATER is a large, pragmatic trial aiming to determine which class of drug when added to levodopa provides the most effective control…
  • 2023 International Congress

    Identification of xylopropamine as a potential dopamine D2 receptor agonist through computational drug discovery pipeline

    B. Ugbedeojo, P. Adoyi, A. Abah, O. Onimisi, S. Musa, A. Omoniyi (Zaria, Nigeria)

    Objective: This study aims to identify novel dopamine D2 receptor agonists through the computational drug discovery pipeline. Background: Parkinson's disease (PD) is a neurodegenerative disorder…
  • 2023 International Congress

    Impulse control disorder related to dopaminergic therapy in progressive supranuclear palsy

    T. Thammongkolchai, P. Termsarasab (Bangkok, Thailand)

    Objective: To report a patient with progressive supranuclear palsy (PSP) in whom an impulse control disorder (ICD) was triggered by a dopaminergic therapy. Background: ICDs…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #29077 (not found)
  • #29056 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28189 (not found)
  • Welcome to the MDS Abstracts Site
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley